Brain scans reveal why some dementia patients lack Self-Awareness
NCT ID NCT06794580
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 77 people with Alzheimer's or frontotemporal dementia to understand why some lose awareness of their condition (anosognosia). Researchers used EEG and brain scans to measure how the brain responds to mistakes and emotional signals. The goal is to find brain markers that could one day help develop tools to improve self-awareness in early dementia.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new ways to detect and improve self-awareness in early dementia, possibly leading to brain-training tools.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. The findings may not lead to practical therapies, and any future applications are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
77 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Nov 2021
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
We plan to recruit a total of 100 subjects, including 30 patients with bvFTD, 30 patients with AD, and 40 healthy, age-, gender-, and education level-matched controls. Since the project aims at investigating the mechanistic cascade that makes bvFTD and AD patients to become unaware of their deficits, the testing of such patients and healthy controls is necessary.
- Ages
-
50 to 85 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: PATIENTS and HEALTHY CONTROLS : * French speakers\*, age ≥ 50 ≤ 85 years of age, with normal color vision or corrected-tonormal visual acuity, * Capacity to consent, * Covered by social security, * Ability to undergo MRI scanning, * The spouse / caregiver is able to accompany the subject to both visits and ready to complete questionnaires. * Already in menopause (for women) PATIENTS : 30 patients fulfilling the core diagnostic features of bvFTD; 30 patients fulfilling the core diagnostic features of AD; both in a mild to moderate cognitive and functional severity stage, as determined by: MMSE score greater than or equal to 18, and CDR global score less than or equal to 2, Grober et Buschke: TRGB \< 42 as well as clinical signs (subjective impression) of anosognosia. HEALTHY SUBJECTS (n=40) : MMSE score ≥ 27;TRGB\> 42 Education, gender-, and aged-matched controls. \* Subjects will be administered neuropsychological tests that have been validated for French speakers. Exclusion Criteria: * Illiteracy /unable to count or to read; * Having a neurological disorder, such as: epilepsy, extrapyramidal signs, brain tumour, subdural haematoma, history of head trauma followed by persistent neurological deficits (motor, sensory or cognitive); stroke that has occurred in the last three months; * Report of a present or prior major psychiatric disorder; * Potentially confounding medications, particularly beta-blockers that may have effects on the peripheral nervous system; typically, beta-blockers are used to control heart rhythm, treat angina, and reduce high blood pressure. * Person deprived of their liberty by judicial or administrative decision * Participation in a drug trial or exclusion period of another study * Inability to understand information about the protocol * Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, claustrophobia) or refusing MRI. \* Contra-indication questionnaire to be filled in beforehand.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A)
Paris, Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a home device slow Alzheimer's? pilot study tests pulsed electromagnetic therapy